Annovis Bio, Inc.
NYSE:ANVSBiotechnology
Healthcare
$1.21 +0.00%
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
52W Low $1.54High $5.50
Volume 1.35M
Average 1.08M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$29.70M
FY 2025 · Annual
Net Income
-$28.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.48M | 16.52M | 38.79M | 20M | 25.22M |
| Selling, General & Admin | 6.06M | 9M | 6.24M | 6.7M | 4.48M |
| Operating Expenses | 14.54M | 25.51M | 45.04M | 26.69M | 29.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (14.5M) | (25.33M) | (56.2M) | (22.74M) | (28.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.54M) | (25.51M) | (45.04M) | (26.69M) | (29.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13.34K | 182.71K | 667.9K | 331.85K | 699.06K |
| Interest Expense | 0 | 0 | 0 | 1.85M | 0 |
| Other Income / Expenses | 50.09K | 182.71K | (11.17M) | 2.1M | 841.06K |
| Income Before Tax | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.90) | (3.10) | (6.23) | (2,018.50) | (1.40) |
| EPS (Diluted) | (1.90) | (3.10) | (6.23) | (2,009.77) | (1.40) |
| 7.63M | 8.16M | 9.02M | 12.18M | 20.55M | |
| 7.63M | 8.16M | 9.02M | 12.24M | 20.55M |
ANVS Earnings Waterfall · TTM
NYSE:ANVS · Revenue to Net Income
Key Ratios
EPS$-1.72
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$40.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.72, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEF 14A | DEF 14A filing | Sep 11, 2026 | |
| PRE 14A | PRE 14A filing | Aug 25, 2026 | |
| 10-Q | Quarterly report | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| 8-K | Current report | Aug 14, 2026 |
How much revenue does ANVS generate?
Annovis Bio, Inc. (ANVS) reported $0.00 of revenue in fiscal 2025.
Is ANVS profitable?
Annovis Bio, Inc. (ANVS) reported -$28.85M of net income.
Continue the stock analysis
Jump to another research area for this company.